Abstract
Angiotensin II (Ang-II) plays a role not only as a vasoconstrictor in controlling blood pressure and electrolyte and fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1 (AT1) receptor in cardiovascular cells. Since a low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors has been reported, the molecular mechanisms of the renin-angiotensin system (RAS) in cancer cells have been elucidated. Interestingly, there is increasing evidence that the RAS is implicated in the development of prostate cancer. As previously reported, AT1 receptor blockers (ARBs), a class of antihypertensive agent, have the potential to inhibit the growth of prostate cancer cells and tumors through the AT1 receptor. This review highlights that the RAS plays a potential role in various aspects of prostate cancer, and ARBs could be useful for treatment of prostate cancer or its chemoprevention.
Keywords: Angiotensin II, angiotensin II receptor blocker, castration resistant prostate cancer, local RAS, prostate cancer, renin-angiotensin system, Dihydrotestosterone, Estradiol, Guanosine phosphate binding protein coupled receptor, Interleukin, Monocyte chemoattractant protein-1, Signal transducer and activator of transcription 3, Tumor necrosis factor, Vascular endothelial factor, Peroxisome proliferator-activated receptor
Current Cancer Drug Targets
Title: Engagement of Renin-Angiotensin System in Prostate Cancer
Volume: 11 Issue: 4
Author(s): H. Uemura, K. Hoshino and Y. Kubota
Affiliation:
Keywords: Angiotensin II, angiotensin II receptor blocker, castration resistant prostate cancer, local RAS, prostate cancer, renin-angiotensin system, Dihydrotestosterone, Estradiol, Guanosine phosphate binding protein coupled receptor, Interleukin, Monocyte chemoattractant protein-1, Signal transducer and activator of transcription 3, Tumor necrosis factor, Vascular endothelial factor, Peroxisome proliferator-activated receptor
Abstract: Angiotensin II (Ang-II) plays a role not only as a vasoconstrictor in controlling blood pressure and electrolyte and fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1 (AT1) receptor in cardiovascular cells. Since a low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors has been reported, the molecular mechanisms of the renin-angiotensin system (RAS) in cancer cells have been elucidated. Interestingly, there is increasing evidence that the RAS is implicated in the development of prostate cancer. As previously reported, AT1 receptor blockers (ARBs), a class of antihypertensive agent, have the potential to inhibit the growth of prostate cancer cells and tumors through the AT1 receptor. This review highlights that the RAS plays a potential role in various aspects of prostate cancer, and ARBs could be useful for treatment of prostate cancer or its chemoprevention.
Export Options
About this article
Cite this article as:
Uemura H., Hoshino K. and Kubota Y., Engagement of Renin-Angiotensin System in Prostate Cancer, Current Cancer Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/156800911795538101
DOI https://dx.doi.org/10.2174/156800911795538101 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In vivo Distribution of Tiotropium in a Rodent Model Utilizing AP-SMALDI Mass Spectrometry Imaging
Current Analytical Chemistry Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Molecular Processes in Cancers and Cancer Chemotherapy
Current Chemical Biology Surface Modification: Approaches and Utilities
Current Applied Polymer Science Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Involvement of PI3K/Akt Pathway in Prostate Cancer - Potential Strategies for Developing Targeted Therapies
Mini-Reviews in Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Designed Multiple Ligands for Cancer Therapy
Current Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Chip-Based High Throughput Screening of Herbal Medicines
Combinatorial Chemistry & High Throughput Screening Vaccine Ingredients: Components that Influence Vaccine Efficacy
Mini-Reviews in Medicinal Chemistry Current Developments on Synthesis, Redox Reactions and Biochemical Studies of Selenium Antioxidants
Current Chemical Biology The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Exploration of Some Thiazolidine-2,4-dione and 2-Oxoindoline Derivatives Incorporating 3,4,5-Trimethoxybenzyl Moiety as Novel Anticancer Agents
Letters in Drug Design & Discovery Leukocyte-Independent Effects of CC-Chemokines on Vascular Remodeling
Current Pharmaceutical Biotechnology